share_log

Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25

Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25

奥本海默重申Relay Therapeutics的跑赢大盘,将目标股价下调至25美元
Benzinga ·  05/06 07:58

Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price target from $33 to $25.

奥本海默分析师马修·比格勒重申了Relay Therapeutics(纳斯达克股票代码:RLAY)的跑赢大盘,并将目标股价从33美元下调至25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发